Suspended PHASE2 INTERVENTIONAL 2-arm NCT06723171

Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

A 4-Week, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of the RXR Agonist Compound IRX4204 for the Treatment of Mild to Moderate Plaque Psoriasis

Sponsor: Io Therapeutics

Conditions Plaque Psoriasis Plaque Type Psorisis Psoriasis

Interventions IRX4204 Placebo

Updated 3 times since 2025 Last updated: Feb 27, 2026 Started: Mar 1, 2026 Primary completion: Mar 31, 2026 Completion: Apr 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

Sponsor request for study hold

This PHASE2 trial investigates Plaque Psoriasis and Plaque Type Psorisis and is currently suspended. Io Therapeutics leads this study, which shows 3 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Mar 2026 — Present [monthly]

Suspended PHASE2

Status: Not Yet Recruiting → Suspended
May 2025 — Mar 2026 [monthly]

Not Yet Recruiting PHASE2
Jan 2025 — May 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Io Therapeutics

Data source: Io Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Webster, United States